On January 5th, the Department of International Cooperation of the China Securities Regulatory Commission issued the "Filing Notice Regarding the Overseas Issuance and Listing of Hangzhou Deshi Biotechnology Co., Ltd. and the 'Full Circulation' of its Domestic Unlisted Shares." Deshi Biotech plans to issue no more than 31.004 million ordinary shares for overseas listing on The Stock Exchange of Hong Kong Limited.

A group of 27 shareholders of the company intend to convert their collectively held 80.88 million domestic unlisted shares into overseas listed shares, which will then be traded on The Stock Exchange of Hong Kong Limited. According to its prospectus, Deshi Biotech has consistently focused on the medical imaging AI industry.

The company's proprietary iMedImageTM features a cross-modal pre-training architecture, enabling a single unified model to support 19 medical imaging modalities, such as chromosomes, CT, MRI, ultrasound, and pathology, covering over 90% of clinical medical imaging scenarios, including reproductive health, hematologic malignancies, and radiological health.

According to Frost & Sullivan data, Deshi Biotech's self-developed iMedImageTM is recognized as the world's largest general-purpose medical imaging foundation model by parameter scale, has been successfully commercialized, and is acknowledged as the world's first commercially available cross-modal medical imaging foundation model.